关键信息
-
基因名
DEFB104A
- 应用
-
别名
DEFB104A；DEFB104；DEFB4；DEFB104B；Beta-defensin 104
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8WTQ1
-
表达区间
23-72aa
-
氨基酸序列
EFELDRICGY GTARCRKKCR SQEYRIGRCP NTYACCLRKW DESLLNRTKP
-
分子量
6.0 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
DEFB104A, also known as human beta-defensin 1 (hBD-1), is a member of the beta-defensin family of antimicrobial peptides that play a crucial role in the innate immune response. These peptides are primarily expressed in various epithelial tissues, including the skin and mucosal surfaces, where they serve as a first line of defense against pathogens. The interest in DEFB104A research has surged due to its broad-spectrum antimicrobial activity, effective against bacteria, viruses, and fungi, as well as its immunomodulatory functions. Studies have shown that this peptide can enhance wound healing and modulate inflammatory responses, making it a potential therapeutic target for treating infections and inflammatory diseases. Additionally, alterations in DEFB104A expression levels have been associated with various health conditions, including respiratory infections and inflammatory disorders. Researchers are exploring methods of recombinant protein production to produce DEFB104A in sufficient quantities for further investigation into its biological properties and potential clinical applications. Understanding the mechanisms of action and regulatory pathways of DEFB104A can yield insights into developing new antimicrobial therapies and improving immune response in vulnerable populations. Thus, the exploration of DEFB104A's potential not only highlights its significance in human health but also opens avenues for innovative therapeutic strategies in combating microbial resistance and enhancing innate immunity.
